Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~A. Patients with any of the following hematologic malignancies:~1. Acute myeloid leukemia (AML) with any of the following:~   1. In first remission (CR1) with intermediate risk or high-risk cytogenetic and/or molecular features.~  2. Patients in second or subsequent complete remission (CR2, CR3, etc.).~  3. Primary refractory or relapsed AML with no more than any one of the following adverse additional features according to modified CIBMTR criteria:49~      * Duration of first CR \< 6 months~     * Poor risk cytogenetics or molecular features (FLT-3 internal tandem duplication (ITD); complex karyotype with ≥3 clonal abnormalities, 5q-/-5, 7q-/-7, 11q23 abnormalities, inv(3), monosomal karyotype)~     * Circulating peripheral blood blasts at time of enrollment~     * Karnofsky performance status \<90%~2. Acute lymphoblastic leukemia (ALL) with any of the following:~   1. In CR1 or subsequent complete remission (CR2, CR3, etc.)~  2. Primary refractory or relapsed ALL with no more than one of the following adverse features according to modified CIBMTR criteria:49~      * Second or subsequent relapse~     * Bone marrow blasts \>25% at time of enrollment~     * Age \>40 years~3. Myelodysplasia with any of the following features:~   1. Refractory anemia with excess blasts type I (5-10% blasts) or II (11-20% blasts) in the bone marrow (RAEB I and II)~  2. Refractory cytopenia with multilineage dysplasia (RCMD) and poor risk cytogenetics (i.e., chromosome 7 abnormalities or complex karyotype with at least 3 abnormalities per clone)~4. Chronic myelogenous leukemia (CML) with one of the following criteria:~   1. Accelerated phase, defined by any of the following:~      * Blasts 10-19% in peripheral blood white cells or bone marrow~     * Peripheral blood basophils at least 20%~     * Persistent thrombocytopenia (\<100 x 109/l) unrelated to therapy, or persistent thrombocytosis (\>1000 x 109/l) unresponsive to therapy~     * Increasing spleen size and increasing white blood cell (WBC) count unresponsive to therapy~     * Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase)~  2. Chronic phase provided a complete hematologic remission was not achieved by 3 months or a complete cytogenetic remission by 18 months and the patient had received at least 2 tyrosine kinase inhibitors~5. Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma, who also have one of the following criteria:~   1. Failure to achieve complete remission to primary induction therapy~  2. Relapsed and refractory to at least one line of salvage systemic therapy~  3. Failed stem cell collection~6. Patients with Hodgkin's lymphoma meeting one of the following criteria:~   1. Primary refractory (failure to achieve complete remission to primary induction therapy)~  2. Relapsed and refractory to at least one line of salvage systemic therapy~  3. Failed stem cell collection~B. Patient age ≥ 18 to ≤ 60 years~C. Karnofsky Performance status ≥ 70%~D. Patients must also receive a full myeloablative preparative regimen (Patients treated with either total body irradiation (TBI)-based or high-dose chemotherapy only regimens are eligible other than high-dose busulfan containing regimens or regimens that include anti-thymocyte globulin or other T cell depleting antibodies)~E. Patients receiving allogeneic peripheral blood stem cell (PBSC) grafts from HLA-matched (5/6 and 6/6 matches) siblings or from well matched unrelated donors (9/10 or 10/10 matches at HLA-A, B, C, DRB1 and DQB1 by high resolution typing) are included. All grafts will be unmanipulated (i.e., no T cell depleted or CD34 selected grafts).~F. No uncontrolled bacterial, viral or fungal infection at time of enrollment defined as currently taking medication and progression of clinical symptoms~G. No HIV disease (Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies)~H. Non-pregnant and non-nursing~I. Required baseline values within 60 days prior to admission:~1. LVEF ≥ 45%~2. DLCO ≥ 50% of predicted (corrected for hemoglobin)~J. Required baseline laboratory values within 16 days prior to admission:~1. Estimated creatinine clearance ≥60 ml/min~2. Serum total bilirubin ≤ 2 x upper limit of normal value (ULN)~3. AST and ALT ≤ 2 x ULN (unless determined by treating physician to be related to underlying malignancy)~K. Signed written informed consent (Patient must be capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent)~L. Patients must otherwise fulfill institutional criteria for eligibility to undergo myeloablative allogeneic stem cell transplantation~EXCLUSION CRITERIA:~A. Symptomatic uncontrolled coronary artery disease or congestive heart failure~B. Severe hypoxemia with room air PaO2 \< 70, supplemental oxygen dependence, or DLCO \< 50% predicted~C. Patients with active central nervous system involvement~D. Prior allogeneic or autologous hematopoietic stem cell transplant in past 12 months~E. Patients with diabetes mellitus requiring insulin secretagogues and/or insulin~F. Patients with hypertriglyceridemia with serum triglyceride level ≥500 mg/d (lipid lowering drugs may be used to control level)~G. Patients with a history of pancreatitis~H. Patients with symptomatic cholelithiasis~I. Patients with a current dependence on alcohol (characterized by a physical addiction to alcohol that interferes with physical or mental health, and social, family or job responsibilities)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin 600 mg q 12 hours PO starting on Day -1 before transplant to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.

Based on this trial design, predict the completion outcome and termination type (if applicable).